Globavir is an infectious disease-focused company with multiple drugs in development. Our development efforts will utilize a 505(b)(2) pathway for therapeutics and will have companion diagnostic tests on the drugs` labels. Our lead program in dengue is expected to be in Phase II in 2015. Our proprietary platform can also generate multiple drug candidates which utilizing the
same 505(b)(2) pathway. Our patent protected diagnostic platform will be applicable for other infectious diseases including West Nile fever, Chickungunya, yellow fever, and malaria.